

Policy Development Branch

SOP Bulletin No. 241

18th March 2024

THE FOLLOWING RMA SOPS TAKE EFFECT ON 26th March 2024

| | |
|---------------------------------------|---|
| New conditions | Myocarditis |
| Revocations & Replacements | Seborrheic keratosis Acute myeloid leukaemia Osteomyelitis Hallux valgus |

NOTEWORTHY FEATURES

Myocarditis

New – 17 & 18 of 2024

- This new SoP defines myocarditis as inflammation of the heart muscle (myocardium) and excludes inflammation associated with coronary artery disease.
- The SoP factors relate to:
 - undergoing a course of radiotherapy for cancer
 - having a myocardial infection, a systemic viral infection, tuberculosis, acute rheumatic fever, a specified form of vasculitides, a specified type of systemic inflammatory diseases, acute pancreatitis, myasthenia gravis, cardiac graft acute cellular rejection, a haematopoietic stem cell transplant, pheochromocytoma or thymoma, a COVID-19 or smallpox vaccine, organophosphate poisoning or paraphenylene diamine poisoning, chronic lead poisoning, and an alcohol use disorder
 - being infected with human immunodeficiency virus
 - being treated with a medication on a specified list
 - being treated with clozapine
 - taking a medication associated in the individual with the clinical onset of myocarditis
 - using cocaine
 - being envenomated
 - ingesting wild mushrooms or toadstools

Seborrheic keratosis

Revocation – 19 & 20 of 2024

Replaces 55 & 56 of 2015

- The definition has been reformatted to the latest RMA format and style. A non-exclusive list of included diagnoses has now been provided with basal cell papilloma, dermatosis papulosa nigra, pigmented seborrheic keratosis, seborrheic wart, stucco keratosis and Leser-Trélat disease all identified as covered by this SoP.
- There are now new factors relating to:
 - having a malignancy that excludes non-melanotic malignant neoplasm of the skin for those with the Leser-Trélat sign (sudden onset of >20 new seborrheic keratoses within 6 months)
 - taking a course of dabrafenib or vemurafenib for the treatment of cancer

- There has been minor updates to the definition with ‘clonal proliferation’ of morphologically immature cells and myeloblasts in ‘other tissues’ now being part of the description (other than just in bone marrow and peripheral blood)
- The definition has been reformatted to the latest RMA format and style and there is now a non-exhaustive list of included and excluded conditions.
- The factor relating to ‘having a haematological disorder’ now has ‘paroxysmal haemoglobinuria’ added for both RH and BoP SoPs. Aplastic anaemia has now also been added to the BoP SoP.
- An additional factor relating to myeloproliferative neoplasm has been added for both RH and BoP SoPs.
- The factor relating to ‘undergoing a course of treatment’ with a specified drug now has:
 - Azathioprine added to the BoP SoP
 - Platinum compounded added to both RH and BoP SoPs
 - Poly(ADP-ribose) polymerase inhibitors (PARP inhibitors) added to both RH and BoP SoPs
 - Granulocyte colony stimulating factor added to the RH SoP
- The factor relating to benzene exposure ‘as specified’ has had the time from exposure to clinical onset reduced from 5 years to 2 years for the RH SoP and from 10 years to 5 years for the BoP SoP.
- The other factor relating to Benzene exposure involving contact with benzene greater than 5ppm-years, has now had the possible routes of exposure specified to be ‘inhaling, ingesting or having cutaneous contact.’
- The factor relating to solid organ transplant or haematopoietic stem cell transplantation, has now been included in the BoP SoP.
- The factor relating to dieldrin, aldrin and diazinon has now been combined with the factor for chlordane and heptachlor into one factor involving specific pesticides for the RH SoP.
- There are new SoP factors relating to inhaling and being exposed to styrene.

Osteomyelitis

Revocation – 23 & 24 of 2024

Replaces 90 & 91 of 2014

- The definition has been reformatted to the latest RMA format and style. Chondritis, septic arthritis and discitis are now explicitly excluded as they involve cartilage.
- Many of the factors have been updated with specific examples provided within the associated notes
- The factor relating to chronic lymphoedema has been removed from both the RH and BoP SoPs
- For the factor relating to having a chronic medical condition, osteopetrosis has now been removed from the specified list of diseases that can be involved at the time of clinical onset of osteomyelitis.
- Both the factors relating to general ionising radiation and radium have been removed

Hallux valgus

Revocation – 25 & 26 of 2024

Replaces 98 & 99 of 2015

- The definition now requires for there to be a ‘symptomatic deformity of the foot.’
- There has been a factor change related to constrictive footwear for the RH and BoP SoPs:
 - ‘wearing footwear that causes lateral deviation of the great toe of the affected foot, on more days than not’ has now been changed to ‘wearing footwear that causes **substantial** lateral deviation of the great toe of the affected foot for **at least 7 hours per day**, on more days than not’
- There have been several changes to the factors relating to inflammatory, depositional and infective arthrosis.
 - Infectious arthritis has now been removed.
 - Factor 2 has been restricted to rheumatoid arthritis. Gout and pseudogout are now described in a separate factor (factor 3). This has been done to aid propagation to the SoPs for rheumatoid arthritis and gout.
- The RH SoP factor relating to pes planus has now been changed to ‘having pes planus before the clinical worsening’ only (i.e. no longer both clinical onset and clinical worsening).
- The factor relating to amputation has been revised to incorporate the definition of ‘amputation of the second toe or the second metatarsal head’ into the description of the factor.

- The factor relating to tumour has been changed from having a tumour ‘before’ to ‘at the time of’ and now also includes the first metatarsophalangeal joint rather than just the second metatarsal bone.
- The factor relating to foot surgery has now been revised with the type of surgical procedures no longer specified.
- The factor relating to trauma has a revised definition of trauma within the description and ‘fracture of the medial side of the first proximal phalanx’ is now considered included.

Contact for this bulletin:

LIABILITY.POLICY.MEDICAL.ADVICE